Mega Genomics Limited (HKSE: 6667.HK) Stock Competitors & Peer Comparison
See 6667.HK's competitors and their performance on the HKSE and across the wider stock market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for 6667.HK and its HKSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 6667.HK | HK$7.19 | -0.42% | 1.6B | 52.52 | HK$0.14 | +2.36% |
| 3774.HK | HK$29.60 | +2.07% | 24.2B | 436.58 | HK$0.07 | N/A |
| 1951.HK | HK$2.19 | -1.35% | 5.8B | 27.57 | HK$0.08 | +1.90% |
| 6078.HK | HK$9.39 | -0.53% | 5.7B | 27.63 | HK$0.34 | N/A |
| 2273.HK | HK$26.48 | -0.08% | 5.6B | 14.97 | HK$1.77 | +6.95% |
| 2373.HK | HK$17.00 | -0.12% | 4.2B | 9.29 | HK$1.83 | +4.24% |
| 2609.HK | HK$2.66 | -0.56% | 3.5B | -266.00 | -HK$0.01 | N/A |
| 1515.HK | HK$2.35 | -0.84% | 3B | 6.24 | HK$0.38 | +6.58% |
| 0708.HK | HK$0.17 | +1.19% | 1.8B | -0.06 | -HK$2.68 | N/A |
| 2219.HK | HK$2.42 | -3.20% | 1.7B | 9.10 | HK$0.27 | +10.03% |
Stock Comparison
Fameglow Holdings Limited (HKSE: 3774.HK)
6667.HK vs 3774.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 3774.HK has a market cap of 24.2B. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 3774.HK trades at HK$29.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 3774.HK's P/E ratio is 436.58. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 3774.HK's ROE of N/A. Regarding short-term risk, 6667.HK is less volatile compared to 3774.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 3774.HK's competition here
Jinxin Fertility Group Limited (HKSE: 1951.HK)
6667.HK vs 1951.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 1951.HK has a market cap of 5.8B. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 1951.HK trades at HK$2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 1951.HK's P/E ratio is 27.57. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 1951.HK's ROE of +0.02%. Regarding short-term risk, 6667.HK is less volatile compared to 1951.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 1951.HK's competition here
Hygeia Healthcare Holdings Co., Limited (HKSE: 6078.HK)
6667.HK vs 6078.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 6078.HK has a market cap of 5.7B. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 6078.HK trades at HK$9.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 6078.HK's P/E ratio is 27.63. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 6078.HK's ROE of +0.03%. Regarding short-term risk, 6667.HK is less volatile compared to 6078.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 6078.HK's competition here
Gushengtang Holdings Limited (HKSE: 2273.HK)
6667.HK vs 2273.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2273.HK has a market cap of 5.6B. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2273.HK trades at HK$26.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2273.HK's P/E ratio is 14.97. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2273.HK's ROE of +0.21%. Regarding short-term risk, 6667.HK is less volatile compared to 2273.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 2273.HK's competition here
Beauty Farm Medical and Health Industry Inc. (HKSE: 2373.HK)
6667.HK vs 2373.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2373.HK has a market cap of 4.2B. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2373.HK trades at HK$17.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2373.HK's P/E ratio is 9.29. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2373.HK's ROE of +0.32%. Regarding short-term risk, 6667.HK is less volatile compared to 2373.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 2373.HK's competition here
Bayzed Health Group, Inc. (HKSE: 2609.HK)
6667.HK vs 2609.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2609.HK has a market cap of 3.5B. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2609.HK trades at HK$2.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2609.HK's P/E ratio is -266.00. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2609.HK's ROE of N/A. Regarding short-term risk, 6667.HK is less volatile compared to 2609.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 2609.HK's competition here
China Resources Medical Holdings Company Limited (HKSE: 1515.HK)
6667.HK vs 1515.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 1515.HK has a market cap of 3B. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 1515.HK trades at HK$2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 1515.HK's P/E ratio is 6.24. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 1515.HK's ROE of +0.06%. Regarding short-term risk, 6667.HK is less volatile compared to 1515.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 1515.HK's competition here
China Evergrande New Energy Vehicle Group Limited (HKSE: 0708.HK)
6667.HK vs 0708.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 0708.HK has a market cap of 1.8B. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 0708.HK trades at HK$0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 0708.HK's P/E ratio is -0.06. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 0708.HK's ROE of -5.68%. Regarding short-term risk, 6667.HK is less volatile compared to 0708.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 0708.HK's competition here
Chaoju Eye Care Holdings Limited (HKSE: 2219.HK)
6667.HK vs 2219.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2219.HK has a market cap of 1.7B. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2219.HK trades at HK$2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2219.HK's P/E ratio is 9.10. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2219.HK's ROE of +0.07%. Regarding short-term risk, 6667.HK is less volatile compared to 2219.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 2219.HK's competition here
Jiangxi Rimag Group Co., Ltd. (HKSE: 2522.HK)
6667.HK vs 2522.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2522.HK has a market cap of 1.7B. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2522.HK trades at HK$4.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2522.HK's P/E ratio is -63.52. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2522.HK's ROE of -0.01%. Regarding short-term risk, 6667.HK is less volatile compared to 2522.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 2522.HK's competition here
Perfect Medical Health Management Limited (HKSE: 1830.HK)
6667.HK vs 1830.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 1830.HK has a market cap of 1.5B. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 1830.HK trades at HK$1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 1830.HK's P/E ratio is 8.25. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 1830.HK's ROE of +0.44%. Regarding short-term risk, 6667.HK is less volatile compared to 1830.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 1830.HK's competition here
Distinct Healthcare Hldg Ltd (HKSE: 2677.HK)
6667.HK vs 2677.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2677.HK has a market cap of 1.4B. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2677.HK trades at HK$22.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2677.HK's P/E ratio is 7.52. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2677.HK's ROE of N/A. Regarding short-term risk, 6667.HK is less volatile compared to 2677.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 2677.HK's competition here
Saint Bella Inc. (HKSE: 2508.HK)
6667.HK vs 2508.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2508.HK has a market cap of 1.4B. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2508.HK trades at HK$2.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2508.HK's P/E ratio is 5.57. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2508.HK's ROE of N/A. Regarding short-term risk, 6667.HK is less volatile compared to 2508.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 2508.HK's competition here
Rici Healthcare Holdings Limited (HKSE: 1526.HK)
6667.HK vs 1526.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 1526.HK has a market cap of 1.4B. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 1526.HK trades at HK$0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 1526.HK's P/E ratio is 4.39. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 1526.HK's ROE of +0.18%. Regarding short-term risk, 6667.HK is less volatile compared to 1526.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 1526.HK's competition here
Town Health International Medical Group Limited (HKSE: 3886.HK)
6667.HK vs 3886.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 3886.HK has a market cap of 1.1B. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 3886.HK trades at HK$0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 3886.HK's P/E ratio is 76.67. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 3886.HK's ROE of +0.00%. Regarding short-term risk, 6667.HK is less volatile compared to 3886.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 3886.HK's competition here
Yonghe Medical Group Co., Ltd. (HKSE: 2279.HK)
6667.HK vs 2279.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2279.HK has a market cap of 1.1B. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2279.HK trades at HK$2.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2279.HK's P/E ratio is 7.80. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2279.HK's ROE of N/A. Regarding short-term risk, 6667.HK is less volatile compared to 2279.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 2279.HK's competition here
Arrail Group Limited (HKSE: 6639.HK)
6667.HK vs 6639.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 6639.HK has a market cap of 1B. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 6639.HK trades at HK$1.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 6639.HK's P/E ratio is 40.33. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 6639.HK's ROE of +0.01%. Regarding short-term risk, 6667.HK is less volatile compared to 6639.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 6639.HK's competition here
Honliv Healthcare Management Group Company Limited (HKSE: 9906.HK)
6667.HK vs 9906.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 9906.HK has a market cap of 936M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 9906.HK trades at HK$1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 9906.HK's P/E ratio is 78.00. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 9906.HK's ROE of +0.06%. Regarding short-term risk, 6667.HK is more volatile compared to 9906.HK. This indicates higher risk in terms of short-term price fluctuations for 6667.HK.Check 9906.HK's competition here
C-MER Medical Holdings Limited (HKSE: 3309.HK)
6667.HK vs 3309.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 3309.HK has a market cap of 921.5M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 3309.HK trades at HK$0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 3309.HK's P/E ratio is 9.18. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 3309.HK's ROE of +0.06%. Regarding short-term risk, 6667.HK is less volatile compared to 3309.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 3309.HK's competition here
BenQ BM Holding Cayman Corp. (HKSE: 2581.HK)
6667.HK vs 2581.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2581.HK has a market cap of 885.9M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2581.HK trades at HK$2.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2581.HK's P/E ratio is 11.92. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2581.HK's ROE of N/A. Regarding short-term risk, 6667.HK is more volatile compared to 2581.HK. This indicates higher risk in terms of short-term price fluctuations for 6667.HK.Check 2581.HK's competition here
Tian An Medicare Limited (HKSE: 0383.HK)
6667.HK vs 0383.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 0383.HK has a market cap of 805.2M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 0383.HK trades at HK$0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 0383.HK's P/E ratio is 30.20. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 0383.HK's ROE of +0.00%. Regarding short-term risk, 6667.HK is more volatile compared to 0383.HK. This indicates higher risk in terms of short-term price fluctuations for 6667.HK.Check 0383.HK's competition here
Wenzhou Kangning Hospital Co., Ltd. (HKSE: 2120.HK)
6667.HK vs 2120.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2120.HK has a market cap of 778.7M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2120.HK trades at HK$11.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2120.HK's P/E ratio is 13.51. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2120.HK's ROE of +0.04%. Regarding short-term risk, 6667.HK is less volatile compared to 2120.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 2120.HK's competition here
Beijing Tong Ren Tang Healthcare Investment Co., Ltd. (HKSE: 2667.HK)
6667.HK vs 2667.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2667.HK has a market cap of 767.8M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2667.HK trades at HK$1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2667.HK's P/E ratio is N/A. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2667.HK's ROE of N/A. Regarding short-term risk, 6667.HK is less volatile compared to 2667.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 2667.HK's competition here
EuroEyes International Eye Clinic Limited (HKSE: 1846.HK)
6667.HK vs 1846.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 1846.HK has a market cap of 762.6M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 1846.HK trades at HK$2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 1846.HK's P/E ratio is 310.39. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 1846.HK's ROE of +0.00%. Regarding short-term risk, 6667.HK is less volatile compared to 1846.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 1846.HK's competition here
Guangdong Kanghua Healthcare Group Co., Ltd. (HKSE: 3689.HK)
6667.HK vs 3689.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 3689.HK has a market cap of 628.7M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 3689.HK trades at HK$1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 3689.HK's P/E ratio is 5.87. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 3689.HK's ROE of +0.06%. Regarding short-term risk, 6667.HK is less volatile compared to 3689.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 3689.HK's competition here
SoftMedx Healthcare Limited (HKSE: 2951.HK)
6667.HK vs 2951.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2951.HK has a market cap of 616.2M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2951.HK trades at HK$5.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2951.HK's P/E ratio is 24.17. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2951.HK's ROE of N/A. Regarding short-term risk, 6667.HK is less volatile compared to 2951.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 2951.HK's competition here
EC Healthcare (HKSE: 2138.HK)
6667.HK vs 2138.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2138.HK has a market cap of 599.4M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2138.HK trades at HK$0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2138.HK's P/E ratio is -1.51. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2138.HK's ROE of -0.25%. Regarding short-term risk, 6667.HK is less volatile compared to 2138.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 2138.HK's competition here
Concord Healthcare Grp Co Ltd (HKSE: 2453.HK)
6667.HK vs 2453.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2453.HK has a market cap of 568.2M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2453.HK trades at HK$0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2453.HK's P/E ratio is -3.23. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2453.HK's ROE of -0.09%. Regarding short-term risk, 6667.HK is less volatile compared to 2453.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 2453.HK's competition here
Kato (Hong Kong) Holdings Limited (HKSE: 2189.HK)
6667.HK vs 2189.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2189.HK has a market cap of 495M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2189.HK trades at HK$0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2189.HK's P/E ratio is 22.62. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2189.HK's ROE of +0.08%. Regarding short-term risk, 6667.HK is less volatile compared to 2189.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 2189.HK's competition here
Hospital Corporation of China Limited (HKSE: 3869.HK)
6667.HK vs 3869.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 3869.HK has a market cap of 462M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 3869.HK trades at HK$3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 3869.HK's P/E ratio is 3.14. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 3869.HK's ROE of -0.00%. Regarding short-term risk, 6667.HK is more volatile compared to 3869.HK. This indicates higher risk in terms of short-term price fluctuations for 6667.HK.Check 3869.HK's competition here
Wuhan Dazhong Dental Medical Co., Ltd. (HKSE: 2651.HK)
6667.HK vs 2651.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2651.HK has a market cap of 439.2M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2651.HK trades at HK$24.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2651.HK's P/E ratio is 47.45. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2651.HK's ROE of N/A. Regarding short-term risk, 6667.HK is less volatile compared to 2651.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 2651.HK's competition here
Beijing Health (Holdings) Limited (HKSE: 2389.HK)
6667.HK vs 2389.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2389.HK has a market cap of 430.2M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2389.HK trades at HK$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2389.HK's P/E ratio is -3.70. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2389.HK's ROE of -0.06%. Regarding short-term risk, 6667.HK is more volatile compared to 2389.HK. This indicates higher risk in terms of short-term price fluctuations for 6667.HK.Check 2389.HK's competition here
Green International Holdings Limited (HKSE: 2700.HK)
6667.HK vs 2700.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2700.HK has a market cap of 382.7M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2700.HK trades at HK$0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2700.HK's P/E ratio is -322.22. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2700.HK's ROE of -0.03%. Regarding short-term risk, 6667.HK is more volatile compared to 2700.HK. This indicates higher risk in terms of short-term price fluctuations for 6667.HK.Check 2700.HK's competition here
Miricor Enterprises Holdings Ltd (HKSE: 1827.HK)
6667.HK vs 1827.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 1827.HK has a market cap of 356M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 1827.HK trades at HK$0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 1827.HK's P/E ratio is 31.67. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 1827.HK's ROE of +0.07%. Regarding short-term risk, 6667.HK is less volatile compared to 1827.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 1827.HK's competition here
UMP Healthcare Holdings Limited (HKSE: 0722.HK)
6667.HK vs 0722.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 0722.HK has a market cap of 324.4M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 0722.HK trades at HK$0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 0722.HK's P/E ratio is -4.25. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 0722.HK's ROE of -0.11%. Regarding short-term risk, 6667.HK is less volatile compared to 0722.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 0722.HK's competition here
Meihao Medical Group Co., Ltd. (HKSE: 1947.HK)
6667.HK vs 1947.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 1947.HK has a market cap of 306.1M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 1947.HK trades at HK$0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 1947.HK's P/E ratio is -17.00. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 1947.HK's ROE of N/A. Regarding short-term risk, 6667.HK is more volatile compared to 1947.HK. This indicates higher risk in terms of short-term price fluctuations for 6667.HK.Check 1947.HK's competition here
Human Health Holdings Limited (HKSE: 1419.HK)
6667.HK vs 1419.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 1419.HK has a market cap of 286.6M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 1419.HK trades at HK$0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 1419.HK's P/E ratio is 10.31. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 1419.HK's ROE of +0.03%. Regarding short-term risk, 6667.HK is more volatile compared to 1419.HK. This indicates higher risk in terms of short-term price fluctuations for 6667.HK.Check 1419.HK's competition here
Hang Chi Holdings Limited (HKSE: 8405.HK)
6667.HK vs 8405.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 8405.HK has a market cap of 276M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 8405.HK trades at HK$0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 8405.HK's P/E ratio is 9.86. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 8405.HK's ROE of +0.12%. Regarding short-term risk, 6667.HK is more volatile compared to 8405.HK. This indicates higher risk in terms of short-term price fluctuations for 6667.HK.Check 8405.HK's competition here
Aidigong Maternal & Child Health Limited (HKSE: 0286.HK)
6667.HK vs 0286.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 0286.HK has a market cap of 251.8M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 0286.HK trades at HK$1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 0286.HK's P/E ratio is -0.86. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 0286.HK's ROE of -0.22%. Regarding short-term risk, 6667.HK is more volatile compared to 0286.HK. This indicates higher risk in terms of short-term price fluctuations for 6667.HK.Check 0286.HK's competition here
Clarity Medical Group Holding Limited (HKSE: 1406.HK)
6667.HK vs 1406.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 1406.HK has a market cap of 191.6M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 1406.HK trades at HK$0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 1406.HK's P/E ratio is -2.54. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 1406.HK's ROE of N/A. Regarding short-term risk, 6667.HK is less volatile compared to 1406.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 1406.HK's competition here
Republic Healthcare Limited (HKSE: 8357.HK)
6667.HK vs 8357.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 8357.HK has a market cap of 129.8M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 8357.HK trades at HK$0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 8357.HK's P/E ratio is -7.49. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 8357.HK's ROE of -0.48%. Regarding short-term risk, 6667.HK is more volatile compared to 8357.HK. This indicates higher risk in terms of short-term price fluctuations for 6667.HK.Check 8357.HK's competition here
New Century Healthcare Holding Co. Limited (HKSE: 1518.HK)
6667.HK vs 1518.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 1518.HK has a market cap of 97.1M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 1518.HK trades at HK$0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 1518.HK's P/E ratio is -0.62. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 1518.HK's ROE of -0.35%. Regarding short-term risk, 6667.HK is more volatile compared to 1518.HK. This indicates higher risk in terms of short-term price fluctuations for 6667.HK.Check 1518.HK's competition here
Raily Aesthetic Medicine International Holdings Limited (HKSE: 2135.HK)
6667.HK vs 2135.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 2135.HK has a market cap of 59.1M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 2135.HK trades at HK$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 2135.HK's P/E ratio is 3.94. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 2135.HK's ROE of +0.12%. Regarding short-term risk, 6667.HK is more volatile compared to 2135.HK. This indicates higher risk in terms of short-term price fluctuations for 6667.HK.Check 2135.HK's competition here
Medicskin Holdings Limited (HKSE: 8307.HK)
6667.HK vs 8307.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 8307.HK has a market cap of 55.5M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 8307.HK trades at HK$0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 8307.HK's P/E ratio is 58.33. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 8307.HK's ROE of +0.20%. Regarding short-term risk, 6667.HK is less volatile compared to 8307.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 8307.HK's competition here
SoftMedx Healthcare Limited (HKSE: 0648.HK)
6667.HK vs 0648.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 0648.HK has a market cap of 41.8M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 0648.HK trades at HK$0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 0648.HK's P/E ratio is 4.96. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 0648.HK's ROE of N/A. Regarding short-term risk, 6667.HK is less volatile compared to 0648.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 0648.HK's competition here
MediNet Group Limited (HKSE: 8161.HK)
6667.HK vs 8161.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 8161.HK has a market cap of 25.8M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 8161.HK trades at HK$0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 8161.HK's P/E ratio is -7.96. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 8161.HK's ROE of -0.32%. Regarding short-term risk, 6667.HK is less volatile compared to 8161.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 8161.HK's competition here
RMH Holdings Limited (HKSE: 8437.HK)
6667.HK vs 8437.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 8437.HK has a market cap of 16.7M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 8437.HK trades at HK$0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 8437.HK's P/E ratio is -0.52. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 8437.HK's ROE of +0.22%. Regarding short-term risk, 6667.HK is more volatile compared to 8437.HK. This indicates higher risk in terms of short-term price fluctuations for 6667.HK.Check 8437.HK's competition here
Good Fellow Healthcare Holdings Limited (HKSE: 8143.HK)
6667.HK vs 8143.HK Comparison October 2026
Mega Genomics Limited (HKSE: 6667.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 6667.HK stands at 1.6B. In comparison, 8143.HK has a market cap of 16M. Regarding current trading prices, 6667.HK is priced at HK$7.19 on the HKSE, while 8143.HK trades at HK$0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
6667.HK currently has a P/E ratio of 52.52, whereas 8143.HK's P/E ratio is -2.76. In terms of profitability, 6667.HK's ROE is +0.04%, compared to 8143.HK's ROE of -1.28%. Regarding short-term risk, 6667.HK is less volatile compared to 8143.HK. This indicates lower risk in terms of short-term price fluctuations for 6667.HK.Check 8143.HK's competition here